



NDA 20845/S-014

SUPPLEMENT APPROVAL

INO Therapeutics
Attention: Mary Ellen Anderson
Senior Director, Regulatory Affairs
Perryville III Corporate Park
53 Frontage Road, Third Floor
Hampton, NJ 08827-9001

Dear Ms. Anderson:

Please refer to your Supplemental New Drug Application (sNDA) dated June 25, 2012, submitted under section 505(b)/pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for INOmax (nitric oxide) for inhalation.

This “Prior Approval” supplemental new drug application provides for labeling revised as follows:

1. Under HIGHLIGHTS/RECENT MAJOR CHANGES, changes to Dosage and Administration have been noted.
2. Under HIGHLIGHTS/DOSAGE AND ADMINISTRATION, the first bullet under “Administration” has been changed from:

INOmax must be delivered via a system which does not cause generation of excessive inhaled nitrogen dioxide (2.2).

To:

Use only with an INOmax DS_{IR}[®], INOmax[®] DS, or INOvent[®] operated by trained personnel (2.2)

3. Under HIGHLIGHTS/DOSAGE AND ADMINISTRATION, the second bullet under “Administration” has been changed from:

Do not discontinue INOmax abruptly (2.2).

To:

Wean from INOmax gradually (2.2).

4. Under HIGHLIGHTS/WARNING AND PRECAUTIONS, the third paragraph has been changed from:

Elevated NO₂ Levels: NO₂ levels should be monitored (5.3)

To:

Elevated NO₂ Levels: Monitor NO₂ levels continuously with a suitable Nitric Oxide Delivery System (5.3)

5. The HIGHLIGHTS/ADVERSE REACTIONS section has been changed from:

Methemoglobinemia and elevated NO₂ levels are dose dependent adverse events. Worsening oxygenation and increasing pulmonary artery pressure occur if INOmax is discontinued abruptly. Other adverse reactions that occurred in more than 5% of patients receiving INOmax in the CINRGI study were: thrombocytopenia, hypokalemia, bilirubinemia, atelectasis, and hypotension (6).

To:

Methemoglobinemia and NO₂ levels are dose dependent. The most common adverse reaction is hypotension (6).

6. FULL PRESCRIBING INFORMATION: CONTENTS has been revised in accordance with changes made to the FULL PRESCRIBING INFORMATION.
7. Under INDICATIONS AND USAGE, “with validated ventilation systems [see Dosage and Administration (2.2)]” has been added to the first sentence of the second paragraph.
8. Under DOSAGE AND ADMINISTRATION, the following has been added as a new first paragraph:
- To ensure safe and effective administration of INOmax to avoid adverse events associated with nitric oxide or NO₂, administration of INOmax should only be performed by a health care professional who has completed and maintained training on the safe and effective use of a Nitric Oxide Delivery System provided by the manufacturer of the delivery system and the drug.
9. Under DOSAGE AND ADMINISTRATION, the Administration section has been significantly revised and now reads as follows:

2.2 Administration

Methemoglobin should be measured within 4-8 hours after initiation of treatment with INOmax and periodically throughout treatment [see Warnings and Precautions (5.2)].

Nitric Oxide Delivery Systems

INOmax must be administered using the INOmax DS_{IR}[®], INOmax[®] DS, or INOvent[®] Nitric Oxide Delivery Systems, which deliver operator-determined concentrations of nitric oxide in conjunction with a ventilator or breathing gas administration system after dilution with an oxygen/air mixture. A Nitric Oxide Delivery System includes a nitric oxide administration apparatus, a nitric oxide gas analyzer and a nitrogen dioxide gas analyzer. Failure to calibrate the Nitric Oxide Delivery System could result in under- or over- dosing of nitric oxide.

To address potential power failure, keep available a backup battery power supply. To address potential system failure, keep available an independent reserve nitric oxide delivery system. Failure to transition to a reserve nitric oxide delivery system can result in abrupt or prolonged discontinuation of nitric oxide [see Warnings and Precautions (5.1)].

Training in Administration

The user of INOmax and Nitric Oxide Delivery Systems must complete a comprehensive training program for health care professionals provided by the delivery system and drug manufacturers.

Health professional staff that administers nitric oxide therapy have access to supplier-provided 24 hour/365 days per year technical support on the delivery and administration of INOmax at 1-877-566-9466.

Weaning and Discontinuation

Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure (PAP) and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation. To wean INOmax, downtitrate in several steps, pausing several hours at each step to monitor for hypoxemia.

10. Under WARNINGS AND PRECAUTIONS, section 5.1 has been revised from:

Rebound

Abrupt discontinuation of INOmax may lead to worsening oxygenation and increasing pulmonary artery pressure.

To:

Rebound Pulmonary Hypertension Syndrome following Abrupt Discontinuation

Wean from INOmax [see *Dosage and Administration (2.2)*]. Abrupt discontinuation of INOmax may lead to worsening oxygenation and increasing pulmonary artery pressure, i.e., Rebound Pulmonary Hypertension Syndrome. Signs and symptoms of Rebound Pulmonary Hypertension Syndrome include hypoxemia, systemic hypotension, bradycardia, and decreased cardiac output. If Rebound Pulmonary Hypertension occurs, reinstate INOmax therapy immediately.

11. Under WARNINGS AND PRECAUTIONS, section 5.2 has been revised from:

Methemoglobinemia

Methemoglobinemia increases with the dose of nitric oxide. In clinical trials, maximum methemoglobin levels usually were reached approximately 8 hours after initiation of inhalation, although methemoglobin levels have peaked as late as 40 hours following initiation of INOmax therapy. In one study, 13 of 37 (35%) of neonates treated with INOmax 80 ppm had methemoglobin levels exceeding 7%. Following discontinuation or reduction of nitric oxide, the methemoglobin levels returned to baseline over a period of hours.

To:

Hypoxia from Methemoglobinemia

Nitric oxide combines with hemoglobin to form methemoglobin, which does not transport oxygen. Methemoglobin levels increase with the dose of INOmax; it can take 8 hours or more before steady-state methemoglobin levels are attained. Monitor methemoglobin and adjust the dose of INOmax to optimize oxygenation.

If methemoglobin levels do not resolve with decrease in dose or discontinuation of INOmax, additional therapy may be warranted to treat methemoglobinemia [see *Overdosage (10)*].

12. Under WARNINGS AND PRECAUTIONS, section 5.3 has been revised from:

Elevated NO₂ Levels

In one study, NO₂ levels were <0.5 ppm when neonates were treated with placebo, 5 ppm, and 20 ppm nitric oxide over the first 48 hours. The 80 ppm group had a mean peak NO₂ level of 2.6 ppm.

To:

Airway Injury from Nitrogen Dioxide

Nitrogen dioxide (NO₂) forms in gas mixtures containing NO and O₂. Nitrogen dioxide may cause airway inflammation and damage to lung tissues. If the concentration of NO₂ in the breathing circuit exceeds 0.5 ppm, decrease the dose of INOmax.

If there is an unexpected change in NO₂ concentration, when measured in the breathing circuit, then the delivery system should be assessed in accordance with the Nitric Oxide Delivery System O&M Manual troubleshooting section, and the NO₂ analyzer should be recalibrated. The dose of INOmax and/or FiO₂ should be adjusted as appropriate.

13. Under WARNINGS AND PRECAUTIONS, section 5.4 has been revised from:

Patients who had pre-existing left ventricular dysfunction treated with inhaled nitric oxide, even for short durations, experienced serious adverse events (e.g., pulmonary edema).

To:

Patients with left ventricular dysfunction treated with INOmax may experience pulmonary edema, increased pulmonary capillary wedge pressure, worsening of left ventricular dysfunction, systemic hypotension, bradycardia and cardiac arrest. Discontinue INOmax while providing symptomatic care.

14. Under ADVERSE REACTIONS/Clinical Trials Experience, Table 1 and the paragraph preceding it have been deleted and replaced with the following text:

In CINRGI, the only adverse reaction (>2% higher incidence on INOmax than on placebo) was hypotension (14% vs. 11%).

15. Under ADVERSE REACTIONS, the Post-Marketing Experience section has been revised and now reads as follows:

Accidental Exposure

Based upon post-marketing experience, accidental exposure to nitric oxide for inhalation in hospital staff has been associated with chest discomfort, dizziness, dry throat, dyspnea, and headache.

16. Under DRUG INTERACTION, the reference to tolazoline has been deleted.
17. Under CLINICAL PHARMACOLOGY/Pharmacokinetics, the numerical subheadings for 12.4, 12.5, and 12.6 have been deleted.
18. Under CLINICAL STUDIES/CINRGI Study, the following has been added to the end of the section:

In clinical trials, reduction in the need for ECMO has not been demonstrated with the use of inhaled nitric oxide in neonates with congenital diaphragmatic hernia (CDH).

19. All REFERENCES in section 15 have been deleted.
20. Under HOW SUPPLIED/STORAGE AND HANDLING, the following text has been added:
- All regulations concerning handling of pressure vessels must be followed.
- Protect the cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.
- The cylinders should be appropriately transported to protect from risks of shocks and falls.
21. Various editorial changes and corrections have been made throughout.
22. The revision dates have been updated.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(1)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.